

CPP-115, The Next Generation GABA-AT Inhibitor

Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) is a biopharmaceutical company focused on the development of CNS drugs for the treatment of epilepsy and addiction. Catalyst has started development of CPP-115, the next generation replacement for vigabatrin (GVG). Both of these anti-epileptic drugs raise GABA levels through the inhibition of GABA-aminotransferase (GABA-AT). By raising both intracellular and extracellular GABA, neuronal excitability is decreased through a stimulus dependent mechanism that we anticipate minimizes both tolerance to the drug and neurological side effects. At a dosage 300 times less than GVG, CPP-115 dampens the cocaine induced dopamine surge in mice better than GVG, confirming the effectiveness, potency and superiority of this drug as a GABA-AT inhibitor. CPP-115 will be tested for anti-epileptic effectiveness, in-vivo, under the NIH's ASP. Catalyst hypothesizes that CPP 115 will result in reduction or elimination of visual field defects, long associated with GVG due to a reduced formation of reactive enzyme deactivation intermediates that have been observed with GVG, but not with CPP-115. Catalyst will be conducting a visual safety study as one of its first development activities to determine the retinotoxicity of CPP-115 relative to GVG. CPP-115 is exclusively licensed to Catalyst and protected by two composition of matter patents expiring in 2023. CPP-115 and GVG are the only known GABA-AT inhibitors. CPP-115 has commercial potential in multiple independent indications related to brain GABA, long patent life, development flexibility in both dosage form and delivery, and has the potential to be a once a day product for epilepsy. Catalyst is seeking a partner or other sources of funding to support its longer term development activities.

For additional information, contact:

Jack Weinstein Steven Miller
CFO, VP Business Development Chief Scientific Officer
Catalyst Pharmaceutical Partners, Inc. Catalyst Pharmaceutical Partners, Inc.
(201) 934-4201 (305) 529-2522
www.catalystpharma.com

Steven Miller
Chief Scientific Officer
Catalyst Pharmaceutical Partners, Inc.
(305) 529-2522